###### Strengths and limitations of this study

-   The current study included a large number of patients with ST segment elevation myocardial infarction (STEMI), with a sufficient number in each chronic kidney disease stage to assure adequate statistical analyses.

-   SWEDEHEART registry is a unique Swedish National Quality registry, with quality control and audit measures, covering all hospitals in Sweden treating patients with STEMI. SWEDEHEART employs standardised criteria for defining myocardial infarction as well as hospital outcomes.

-   Long-term outcome is complete in Sweden as the vital status of all citizens is registered in the Cause of Death Registry.

-   One of the limitations of SWEDEHEART is its non-randomised, observational nature. Thus multivariate analyses were used in order to reduce the bias inherent in this type of study.

-   The calculations of estimated glomerular filtration rate were based on serum creatinine (s-creatinine) on admission. Thus we cannot exclude inclusion of a few patients with acute renal failure, where the admission s-creatinine may not represent a true estimation of the baseline kidney function.

Introduction {#s1}
============

During the past decade, chronic kidney disease (CKD) has been found to be one of the most important prognostic markers after myocardial infarction (MI). Even mildly reduced kidney function affects the prognosis in acute coronary syndrome.[@R1] As soon as a value of 70--90 mL/min has been reached, each 10 mL decline in estimated glomerular filtration rate (eGFR) increases the risk of mortality by 10--14% post-MI.[@R1] [@R6] In addition to prognostic information, it is important to be aware of the presence of CKD in ST segment elevation MI (STEMI), as the majority of patients will undergo primary percutaneous coronary intervention (PCI) with a contrast load that may cause deterioration in an already reduced kidney function. Cardiologists have gradually improved their ability to evaluate kidney function as one part of the overall risk assessment and also to aid in making drug dose adjustments. The Cockcroft-Gault (CG)[@R7] and the Modification of Diet in Renal Disease Study (MDRD)[@R8] formulas are the most widely used, but they differ in several important respects. MDRD is recommended for detecting CKD and CG is recommended for making drug dose adjustments. CG has been shown to be somewhat more predictive of mortality than MDRD after MI.[@R9]

In STEMI, female gender has been independently associated with an increased risk of mortality, especially in the early phase.[@R10] Gender differences in the prevalence and prognostic impact of CKD in STEMI have been poorly evaluated in the literature. According to a small single-centre study on patients with STEMI, women had CKD more often than men (67% vs 27%), according to MDRD, and CKD had a stronger prognostic impact in women.[@R13]

Thus the first objective of the present study was to evaluate the prevalence of the different stages of CKD in women and men with STEMI and to examine whether female gender is an independent predictor of CKD. The second objective was to evaluate the prognostic impact of CKD on short-term and long-term mortality, and examine if there is an interaction between gender and CKD regarding prognosis. The third objective was to evaluate if female gender is independently associated with increased short-term and long-term mortality after adjusting for CKD.

Methods {#s2}
=======

Patient population {#s2a}
------------------

All consecutive patients with STEMI admitted to coronary care units (CCUs) between 2003 and 2009 registered in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) register were included in the current study (<http://www.ucr.uu.se/swedeheart>). The details of the register have been previously published.[@R14] In the beginning of the study period, 94% of the Swedish CCUs contributed with data to the register, increasing to 100% towards the end of the study period.

SWEDEHEART was also merged with the National Patient Registry (PAR) and the National Death Register. Data on prior comorbidities such as previous MI, diabetes mellitus (DM), stroke, heart failure, dementia, chronic obstructive pulmonary disease (COPD), peripheral artery disease (PAD) and cancer were obtained from the PAR, which collects all discharge diagnoses for patients admitted to a hospital in Sweden since 1987. For the current study, a patient was coded as having one of the mentioned diagnoses if apparent in either SWEDEHEART or PAR. Mortality data were available for all patients and were obtained both from the SWEDEHEART (in-hospital mortality) and the National Death Register (long-term mortality).

Definitions {#s2b}
-----------

On the basis of serum creatinine (s-creatinine) on admission, GFR was estimated with the MDRD, and Creatinine Clearance with the CG formulas, for all patients where data on sex, age and s-creatinine were available, and regarding CG, also weight.

Renal dysfunction was staged according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) definition; eGFR\>90 mL/min/1.73 m^2^ (normal), 60--90 mL/min/1.73 m^2^ (mild), 30--59 mL/min/1.73 m^2^ (moderate), 15--29 mL/min/1.73 m^2^ (severe) and \<15 mL/min/1.73 m^2^ or receiving dialysis (renal failure).[@R15] CKD stages 4 and 5 were analysed together in the multivariate analysis of the effect of CKD class on mortality, as we had few patients in CKD stage 5, otherwise the classes are presented separately. In order to simplify, the term eGFR will be used for both formulas from here on. CKD is defined as eGFR\<60 mL/min(/1.73 m^2^). In [table 1](#BMJOPEN2015008188TB1){ref-type="table"}, the MDRD formula is used to define the CKD group. GFR estimated according to MDRD in mL/min/1.73 m^2^=186 \* (serum creatinine/88.4 \[in µmol/L\])^−1.154^ \* age \[in years\]) ^−0.203^ If women multiply the equation by 0.742CrCl according to CG in mL/min=((140- age \[in years\]) \* weight \[in kilogram\])/(serum creatinine \[in µmol/L\]) \* (88.4/72) If women multiply the equation by 0.85

###### 

Baseline characteristics

                                                 All women (n=12 929)   CKD\* (n=4589)   Non-CKD\* (n=7454)   p Value†     All men (n=25 062)   CKD\* (n=4415)   Non-CKD\* (n=18 902)   p Value†   p Value‡
  ---------------------------------------------- ---------------------- ---------------- -------------------- ------------ -------------------- ---------------- ---------------------- ---------- ----------
  Age in years, mean (SD)                        73.7 (12.1)            79.4 (9.3)       70.2 (12.3)          \<0.001      66.3 (12.2)          75.5 (10.2)      64.2 (11.6)            \<0.001    \<0.001
  Weight in kg, mean (SD)                        68.4 (13.9)            67.8 (13.8)      68.8 (14.0)          0.001        82.8 (13.7)          80.1 (14.0)      83.3 (13.6)            \<0.001    \<0.001
  Body mass index in kg/m^2^, mean (SD)          26.1 (8.6)             25.9 (4.8)       26.1 (10.2)          0.44         26.7 (5.1)           26.2 (8.6)       26.7 (4.1)             \<0.001    \<0.001
  Systolic blood pressure in mm Hg, mean (SD)    139.5 (31.2)           135.8 (32.8)     142.1 (29.6)         \<0.001      140.1 (29.0)         133.9 (31.2)     141.8 (28.2)           \<0.001    0.09
  Heart rate in bpm, mean (SD)                   79.1 (22.2)            80.8 (24.9)      78.2 (20.5)          \<0.001      75.9 (20.4)          79.2 (24.7)      75.1 (19.2)            \<0.001    \<0.001
  Medical history                                                                                                                                                                                  
   Current smoker                                3167 (27.2)            614 (15.4)       2376 (34.3)          \<0.001      7126 (30.6)          700 (18.0)       5979 (33.4)            \<0.001    \<0.001
   Previous myocardial infarction                2187 (17.1)            1133 (25.0)      865 (11.7)           \<0.001      4473 (18.0)          1339 (30.7)      2759 (14.7)            \<0.001    0.03
   Previous percutaneous coronary intervention   542 (4.2)              196 (4.3)        305 (4.1)            0.58         1831 (7.4)           359 (8.3)        1347 (7.2)             0.01       \<0.001
   Previous coronary artery bypass grafting      280 (2.2)              134 (2.9)        120 (1.6)            \<0.001      1100 (4.4)           320 (7.3)        691 (3.7)              \<0.001    \<0.001
   Diabetes mellitus                             2808 (21.8)            1286 (28.2)      1326 (17.9)          \<0.001      4676 (18.8)          1132 (25.8)      3244 (17.2)            \<0.001    \<0.001
   Hypertension                                  5954 (46.8)            2534 (56.3)      3061 (41.6)          \<0.001      8615 (34.9)          2112 (48.8)      5950 (31.9)            \<0.001    \<0.001
   Previous heart failure                        1455 (11.3)            933 (20.3)       398 (5.3)            \<0.001      1558 (6.2)           735 (16.7)       690 (3.7)              \<0.001    \<0.001
   Previous stroke                               1500 (11.6)            743 (16.2)       640 (8.6)            \<0.001      2196 (8.8)           764 (17.3)       1278 (6.8)             \<0.001    \<0.001
   Peripheral artery disease                     565 (4.4)              305 (6.7)        214 (2.9)            \<0.001      860 (3.4)            354 (8.0)        434 (2.3)              \<0.001    \<0.001
   Chronic obstructive pulmonary disease         1264 (9.8)             473 (10.3)       714 (9.6)            0.19         1403 (5.6)           340 (7.7)        967 (5.1)              \<0.001    \<0.001
   Cancer within 3 years                         402 (3.1)              176 (3.8)        187 (2.5)            \<0.001      806 (3.2)            265 (6.0)        480 (2.5)              \<0.001    0.57
  Therapy on arrival                                                                                                                                                                               
   Aspirin                                       4149 (32.5)            1965 (43.3)      1869 (25.3)          \<0.001      6773 (27.3)          1888 (43.4)      4336 (23.1)            \<0.001    \<0.001
   Other platelet inhibitor                      571 (4.5)              234 (5.2)        259 (3.5)            \<0.001      1029 (4.1)           249 (5.7)        641 (3.4)              \<0.001    0.14
   β-blocker                                     4503 (35.4)            2088 (46.3)      2087 (28.3)          \<0.001      6835 (27.6)          1849 (42.6)      4442 (23.7)            \<0.001    \<0.001
   ACE inhibitor                                 1957 (15.4)            942 (20.9)       845 (11.4)           \<0.001      3522 (14.2)          1001 (23.1)      2224 (11.9)            \<0.001    0.003
   Angiotensin receptor blocker                  996 (9.9)              451 (12.9)       515 (8.3)            \<0.001      1557 (7.9)           442 (13.2)       1065 (6.8)             \<0.001    \<0.001
   Statin                                        2075 (16.3)            828 (18.3)       1089 (14.8)          \<0.001      4455 (18.0)          1007 (23.3)      3118 (16.6)            \<0.001    \<0.001
  Procedures/therapies at CCU/cath lab                                                                                                                                                             
   Coronary angiography                          8068 (62.6)            2419 (52.9)      5154 (69.2)          \<0.001      18 725 (75.0)        2610 (59.3)      14 938 (79.1)          \<0.001    \<0.001
   Reperfusion therapy                           8976 (69.4)            2464 (53.7)      5964 (80.0)          \<0.001      21 121 (84.3)        2868 (65.0)      16 852 (89.2)          \<0.001    \<0.001
  Biochemical markers, mean (SD)                                                                                                                                                                   
   Total cholesterol (mmol/L)                    5.2 (1.3)              5.1 (1.3)        5.2 (1.2)            0.02         4.9 (1.2)            4.6 (1.2)        5.0 (1.1)              \<0.001    \<0.001
   Low-density lipoprotein (mmol/L)              3.1 (1.0)              3.0 (1.3)        5.2 (1.2)            \<0.001      3.0 (1.0)            2.8 (1.0)        3.1 (1.0)              \<0.001    \<0.001
   Plasma glucose (mmol/L)                       8.2 (3.5)              9.8 (4.9)        8.2 (3.4)            \<0.001      8.2 (3.5)            9.2 (4.7)        7.9 (3.2)              \<0.001    \<0.001
   Haemoglobin (g/L)                             130.5 (15.5)           126.7 (16.5)     132.5 (14.5)         \<0.001      142.8 (15.8)         135.0 (18.7)     144.3 (14.7)           \<0.001    \<0.001
   Troponin T (ng/L)                             5.2 (31.0)             6.0 (35.6)       4.3 (28.5)           \<0.001      6.0 (29.5)           8.4 (51.4)       5.1 (20.6)             \<0.001    0.06
   Creatinine (umol/L)                           88.8 (51.6)            125.3 (68.0)     66.4 (11.3)          \<0.001      98.8 (54.3)          162.7 (98)       83.8 (14.2)            \<0.001    \<0.001
   eGFR according to MDRD (mL/min/1.73 m^2^)     69.4 (28.3)            43.7 (12.3)      85.2 (23.3)          \<0.001      80.7 (29.6)          45.0 (12.7)      89.0 (26.0)            \<0.001    \<0.001
   eGFR according to CG (mL/min)                 65.5 (32.7)            39.5 (15.4)      80.0 (30.7)          \<0.001      88.2 (37.1)          45.5 (16.8)      97.0 (33.9)            \<0.001    \<0.001
  Complications                                                                                                                                                                                    
   Killip class I (no signs of heart failure)    9488 (79.7)            2980 (70.0)      5980 (86.9)          \<0.001      20 136 (87.2)        3054 (74.6)      15 879 (90.8)          \<0.001    \<0.001
   Killip class II (rales)                       1586 (13.3)            820 (19.3)       643 (9.3)            1936 (8.4)   650 (15.9)           1124 (6.4)                                         
   Killip class III (pulmonary oedema)           230 (1.9)              136 (3.2)        76 (1.1)             207 (0.9)    103 (2.5)            91 (0.5)                                           
   Killip class IV (cardiogenic shock)           606 (5.1)              320 (7.5)        185 (2.7)                         812 (3.5)            285 (7.0)        393 (2.2)                         
   Ejection fraction ≤50%                        4350 (56.4)            1638 (67.3)      2559 (51.2)          \<0.001      9382 (55.7)          7068 (52.3)      1964 (72.6)            \<0.001    0.33
   2nd--3rd degree atrioventricular block        442 (3.4)              237 (5.2)        169 (2.3)            \<0.001      629 (2.5)            213 (4.9)        376 (2.0)              \<0.001    \<0.001
   Major bleeding                                348 (3.1)              172 (4.5)        161 (2.4)            \<0.001      346 (1.6)            133 (3.6)        202 (1.2)              \<0.001    \<0.001
   Reinfarction                                  249 (2.0)              120 (2.7)        106 (1.4)            \<0.001      385 (1.6)            120 (2.8)        238 (1.3)              \<0.001    \<0.001
  Therapy at discharge                                                                                                                                                                             \<0.001
   Aspirin                                       10 966 (86.1)          3591 (79.9)      6740 (91.0)          \<0.001      22 570 (90.9)        3565 (82.1)      17 603 (93.6)          \<0.001    \<0.001
   Other platelet inhibitor                      8344 (65.5)            2351 (52.3)      5601 (75.7)          \<0.001      18 913 (76.1)        2567 (59.2)      15 338 (81.5)          \<0.001    \<0.001
   β-blockers                                    10 509 (82.6)          3473 (77.4)      6419 (86.7)          \<0.001      21 814 (87.9)        3436 (79.2)      17 001 (90.4)          \<0.001    \<0.001
   ACE inhibitor                                 6710 (52.8)            2089 (46.5)      4263 (57.7)          \<0.001      15 123 (61.0)        2224 (51.3)      12 123 (64.5)          \<0.001    \<0.001
   Angiotensin receptor blocker                  1026 (10.1)            427 (12.2)       572 (9.1)            \<0.001      1658 (8.4)           414 (12.3)       1198 (7.6)             \<0.001    \<0.001
   Statins                                       8863 (69.7)            2521 (56.2)      5891 (79.6)          \<0.001      20 475 (82.5)        280 (64.8)       16 524 (87.9)          \<0.001    \<0.001
  Outcome                                                                                                                                                                                          
   In-hospital mortality                         1422 (11.0)            849 (18.5)       379 (5.1)            \<0.001      1380 (5.5)           675 (15.3)       494 (2.6)              \<0.001    \<0.001
   One year mortality                            2473 (21.0)            1419 (33.6)      773 (11.5)           \<0.001      2657 (11.7)          1226 (30.2)      1139 (6.7)             \<0.001    \<0.001
   Long-term mortality§                          5041 (20.1)            2368 (51.6)      1505 (20.2)          \<0.001      4312 (33.4)          2038 (46.2)      2501 (13.2)            \<0.001    \<0.001

Table figures refer to counts (percentages) if not otherwise indicated.

\*CKD defined as eGFR \<60 mL/min/1.73 m^2^ according to MDRD.

†Comparison between CKD and non-CKD.

‡Comparison between all men and all women.

§Median follow-up 1152 days.

Cath lab, catheterisation laboratory; CCU, coronary care unit; CG, Cockcroft-Gault formula; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study formula.

Acute MI was diagnosed using current guidelines during the years of inclusion[@R16] [@R17] if troponin T or I or two successive creatine kinase MB (CK-MB) values were above the 99th percentile for the reference population within 24 h of the index clinical event, or if the CK-MB value was twice above the decision limit. STEMI was defined as having a significant ST segment elevation on arrival-ECG together with the diagnosis of MI on discharge, that is, patients with left bundle branch block or pacemaker-ECG on admission were excluded. If a patient was registered with MI several times in SWEDEHEART, only the first occasion was counted.

Ethics {#s2c}
------

All patients for whom data are entered into the SWEDEHEART register are informed of their participation and their right to deny participation or have data removed later, in accordance to Swedish legislation. Data used for research purpose have all personal identifiers removed. The registry and the merging of registries are approved by the Swedish National Board of Health and Welfare.

Statistics {#s2d}
----------

Continuous variables were summarised by their mean and SD, or median and IQR, as appropriate. Categorical variables were summarised by counts and percentages. Comparisons between different groups were performed by χ^2^ tests for categorical variables and by Student t test or Mann-Whitney test for continuous variables. p Values \<0.05 were considered to indicate statistical significance.

Crude and multivariable ORs with 95% CIs were calculated from logistic regression analyses in order to compare men and women as regards risk of having CKD. Variables incorporated in the model were: gender, age, smoking, previous MI, PCI, coronary artery bypass grafting, stroke, hypertension, DM, COPD, heart failure, PAD, dementia, cancer within 3 years, and therapy on arrival (aspirin, other platelet inhibitors, oral anticoagulants, β-blockers, ACE inhibitors, angiotensin receptor blockers (ARB), statins, calcium-channel blockers (CCB), diuretics, digitalis and long-acting nitrates).

Crude and multivariable adjusted ORs and HRs with 95% CI were calculated using logistic and Cox proportional hazard regression analyses in order to evaluate the impact of eGFR on in-hospital and long-term mortality, respectively. Men and women were analysed separately. The same variables as above (except gender) were used with the addition of interventional hospital, year of inclusion, reperfusion therapy and Killip class regarding in-hospital mortality and also discharge therapy regarding long-term mortality. Kaplan-Meier survival curves were plotted for men and women in four CKD categories, according to MDRD and CG, respectively. Wilcoxon (Gehan) Statistics were used for comparisons between the CKD groups.

Finally, a possible interaction between gender and eGFR regarding mortality was evaluated incorporating an interaction term (ie, the product of gender and eGFR) into logistic and Cox regression models, respectively, together with gender and eGFR and all other covariates.

All statistical analyses were performed with SPSS V.18.0 (PASW Statistics V.18) software (SPSS Inc, Chicago, Illinois, USA).

Results {#s3}
=======

Basic characteristics {#s3a}
---------------------

A total of 37 991 patients were included in the analyses, 25 062 (66%) men and 12 929 (34%) women. Women were older, had lower weight, body mass index (BMI), heart rate and Killip class on admission. They also had a higher prevalence of comorbidities such as diabetes, hypertension, COPD, PAD, previous stroke or dementia whereas men were more often smokers, had more often suffered from a previous MI and had more often been previously revascularised ([table 1](#BMJOPEN2015008188TB1){ref-type="table"}).

Complete data were available for 35 352 (93%) patients regarding MDRD and 26 586 (70%) patients regarding CG.

Patients with CKD, men and women, were older, had lower weight, BMI and systolic blood pressure but higher heart rate on admission, compared with patients with without CKD. The prevalence of cardiovascular risk factors and diseases, such as diabetes, hypertension, previous stroke, PAD, chronic heart failure or previous MI were higher in the patients with CKD but they were half as often smokers compared with the patients without CKD. Almost half of the CKD men and women were already on treatment with aspirin or β-blockers on admission. They had higher plasma glucose on admission and lower haemoglobin and cholesterol levels. They much more often had signs of heart failure including cardiogenic shock or pulmonary oedema and all complications during hospital care were more common among patients with CKD of both genders. Around 70% of the women and 50% of the men with CKD had left ventricular dysfunction (ejection fraction \<50%) compared with half of the men and women without CKD. They had a lower chance of reperfusion therapy or angiography during hospital care and less often received evidence-based cardiovascular therapies such as platelet inhibitors or statins at the time of discharge ([table 1](#BMJOPEN2015008188TB1){ref-type="table"}).

Differences between men and women in kidney function {#s3b}
----------------------------------------------------

Mean s-creatinine on admission was higher in men whereas mean eGFR was lower in women regardless of formula. Mean eGFR was 69 and 66 mL/min in women compared with 81 and 88 mL/min in men, using MDRD and CG formulas, respectively ([table 1](#BMJOPEN2015008188TB1){ref-type="table"}). About 19% and 22% of men versus 38% and 50% of women had CKD according to the MDRD and CG formulas, respectively. Among men, 33% and 45% were in the best CKD stage compared with 20% and 19% among women according to both formulas. In the youngest group, more than 90% of men and 75% of women were in CKD stage 1 compared with only a few per cent of men and women in the oldest group according to CG ([figure 1](#BMJOPEN2015008188F1){ref-type="fig"} and [table 2](#BMJOPEN2015008188TB2){ref-type="table"}).

###### 

Prevalence of CKD stage 1--5 in women and men, MDRD and CG

                       Women (n=12 929)   Men (n=25 062)   p Value
  -------------------- ------------------ ---------------- ---------
  MDRD study formula   (n=12 043)         (n=23 317)       
   CKD stage 1         2400 (19.9)        7623 (32.7)      \<0.001
   CKD stage 2         5054 (42.0)        11 279 (48.4)    
   CKD stage 3         3891 (32.3)        3801 (16.3)      
   CKD stage 4         579 (4.8)          464 (2.0)        
   CKD stage 5         119 (1.0)          150 (0.6)        
  CG formula           (n=8794)           (n=17 792)       
   CKD stage 1         1675 (19.0)        7940 (44.6)      \<0.001
   CKD stage 2         2731 (31.1)        5964 (33.5)      
   CKD stage 3         3487 (39.7)        3366 (18.9)      
   CKD stage 4         789 (9.0)          428 (2.4)        
   CKD stage 5         112 (1.3)          94 (0.5)         

Data presented as numbers (percentages) if not otherwise noticed.

CG, Cockcroft-Gault; CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease.

![Chronic kidney disease (CKD) stages according to Modification of Diet in Renal Disease Study (MDRD) (left) and Cockcroft-Gault (CG) (right) in five age-groups.](bmjopen2015008188f01){#BMJOPEN2015008188F1}

After adjustment for age, women had 1.6 and 2.2 times higher risk of having CKD with the MDRD and CG formula, respectively, which did not change after multivariable adjustment. The odds of being classified as having CKD were significantly higher when the CG was used instead of the MDRD formula. This result persisted even when cut-points for mild (eGFR\<90 mL/min/1.73 m^2^) or severe (eGFR\<30 mL/min/1.73 m^2^) CKD were used ([table 3](#BMJOPEN2015008188TB3){ref-type="table"}).

###### 

Risk of chronic kidney disease in women compared with men

                               Crude OR (95% CI)     Age adjusted OR (95% CI)   Multivariable adjusted OR (95% CI)\*
  ---------------------------- --------------------- -------------------------- --------------------------------------
  MDRD (n=35 360)                                                               
   Risk of eGFR\<30            2.27 (2.04 to 2.55)   1.43 (1.27 to 1.61)        1.30 (1.11 to 1.47)
   Risk of eGFR\<60            2.64 (2,51 to 2.77)   1.64 (1.56 to 1.74)        1.58 (1.48 to 1.68)
   Risk of eGFR\<90            1.95 (1.85 to 2.06)   1.32 (1.24 to 1.39)        1.30 (1.22 to 1.38)
  Cockcroft-Gault (n=26 586)                                                    
   Risk of eGFR\<30            3.78 (3.38 to 4.22)   1.92 (1.71 to 4.04)        1.85 (1.61 to 2.12)
   Risk of eGFR\<60            3.56 (3.37 to 3.76)   2.20 (2.05 to 2.36)        2.18 (2.02 to 2.36)
   Risk of eGFR\<90            3.43 (3.22 to 3.64)   2.30 (2.13 to 2.49)        2.29 (2.11 to 2.49)

\*Logistic regression analyses adjusted for age, smoking, diabetes, hypertension, previous myocardial infarction, previous percutaneous coronary intervention, previous coronary artery bypass grafting, chronic heart failure, previous stroke, chronic obstructive pulmonary disease, dementia, peripheral artery disease, previous cancer and therapy on arrival.

eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study formula.

Outcome, CKD versus non-CKD {#s3c}
---------------------------

Nineteen per cent of women with CKD compared with 5% of women without CKD died during hospital care. The corresponding figures in men were 15% vs 3%. During follow-up, 52% of women with CKD died compared with 20% of women without CKD. Corresponding figures in men were 46% vs 13%. In both genders, after multivariable adjustments, in-hospital and long-term mortality gradually increased per 10 mL decline of eGFR and per incline in CKD stage according to both formulas ([table 4](#BMJOPEN2015008188TB4){ref-type="table"} and [figure 2](#BMJOPEN2015008188F2){ref-type="fig"}). There was no significant interaction between gender and eGFR regarding in-hospital mortality (MDRD, p=0.07/CG, p=0.44) or long-term mortality (MDRD, p=0.83/CG, p=0.56).

###### 

Influence of reduced eGFR on short-term and long-term mortality

                               Crude OR (95% CI)        Age adjusted OR/HR (95% CI)   Multivariable adjusted OR/HR\* (95% CI)
  ---------------------------- ------------------------ ----------------------------- -----------------------------------------
  *Men, MDRD (N=23 313)*                                                              
  In-hospital mortality                                                               
   Per 10 mL/min decline       1.52 (1.48 to 1.56)      1.35 (1.31 to 1.39)           1.33 (1.18 to 1.28)
   CKD compared with non-CKD   6.73 (5.96 to 7.60)      3.41 (2.99 to 3.89)           2.59 (2.19 to 3.07)
   CKD stage 1 (n=7623)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=11 277)      2.25 (1.82 to 2.77)      1.50 (1.21 to 1.85)           1.38 (1.07 to 1.77)
   CKD stage 3 (n=3797)        9.50 (7.73 to 11.68)     3.79 (3.04 to 4.72)           2.76 (2.12 to 3.60)
   CKD stage 4--5 (n=612)      28.92 (22.50 to 37.17)   11.30 (8.66 to 14.75)         7.23 (5.18 to 10.09)
  Long-term mortality                                                                 
   Per 10 mL/min decline       1.36 (1.34 to 1.38)      1.19 (1.18 to 1.21)           1.09 (1.07 to 1.11)
   CKD compared with non-CKD   4.29 (4.06 to 4.55)      2.16 (2.02 to 2.30)           1.57 (1.43 to 1.72)
   CKD stage 1 (n=7623)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=11 277)      1.63 (1.50 to 1.78)      1.07 (0.98 to 1.17)           1.09 (0.97 to 1.22)
   CKD stage 3 (n=3797)        5.19 (4.75 to 5.67)      1.99 (1.81 to 2.19)           1.56 (1.37 to 1.77)
   CKD stage 4--5 (n=612)      13.27 (11.76 to 14.97)   5.03 (4.43 to 5.71)           2.55 (2.12 to 3.06)
  *Women, MDRD (N=12 039)*                                                            
  In-hospital mortality                                                               
   Per 10 mL/min decline       1.42 (1.38 to 1.46)      1.29 (1.25 to 1.33)           1.28 (1.23 to 1.33)
   CKD compared with non-CKD   4.24 (3.73 to 4.82)      2.57 (2.25 to 2.94)           2.01 (1.69 to 2.38)
   CKD stage 1 (n=2400)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=5054)        1.76 (1.37 to 2.26)      1.22 (0.94 to 1.57)           1.25 (0.93 to 1.71)
   CKD stage 3 (n=3887)        5.14 (4.06 to 6.52)      2.42 (1.89 to 3.10)           1.96 (1.45 to 2.66)
   CKD stage 4--5 (n=697)      15.83 (12.10 to 20.72)   7.31 (5.52 to 9.68)           5.62 (3.95 to 8.00)
  Long-term mortality                                                                 
   Per 10 mL/min decline       1.33 (1.31 to 1.35)      1.20 (1.18 to 1.22)           1.11 (1.09 to 1.14)
   CKD compared with non-CKD   3.10 (2.91 to 3.31)      1.87 (1.75 to 2.01)           1.47 (1.34 to 1.62)
   CKD stage 1 (n=2400)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=5054)        1.44 (1.28 to 1.62)      0.99 (0.88 to 1.11)           1.05 (0.89 to 1.23)
   CKD stage 3 (n=3887)        3.47 (3.10 to 3.88)      1.61 (1.44 to 1.81)           1.37 (1.17 to 1.61)
   CKD stage 4--5 (n=697)      9.22 (8.08 to 10.54)     4.10 (3.57 to 4.70)           2.79 (2.30 to 3.39)
  *Men, CG (N=17 792)*                                                                
  In-hospital mortality                                                               
   Per 10 mL/min decline       1.51 (1.46 to 1.56)      1.36 (1.31 to 1.42)           1.29 (1.23 to 1.36)
   CKD compared with non-CKD   7.92 (6.71 to 9.35)      3.15 (2.56 to 3.89)           2.49 (1.95 to 3.17)
   CKD stage 1 (n=7940)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=5962)        2.86 (2.15 to 3.80)      1.61 (1.19 to 2.19)           1.48 (1.05 to 2.08)
   CKD stage 3 (n=3363)        11.29 (8.70 to 14.66)    3.91 (2.81 to 5.42)           2.97 (2.05 to 4.31)
   CKD stage 4--5 (n=521)      36.47 (26.83 to 49.57)   11.47 (7.86 to 16.74)         7.07 (4.55 to 10.99)
  Long-term mortality                                                                 
   Per 10 mL/min decline       1.41 (1.39 to 1.43)      1.21 (1.19 to 1.24)           1.11 (1.08 to 1.13)
   CKD compared with non-CKD   5.43 (5.04 to 5.84)      2.00 (1.82 to 2.19)           1.43 (1.27 to 1.60)
   CKD stage 1 (n=7940)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=5962)        2.32 (2.07 to 2.60)      1.16 (1.02 to 1.32)           1.18 (1.01 to 1.37)
   CKD stage 3 (n=3363)        7.20 (6.47 to 8.01)      2.00 (1.74 to 2.30)           1.53 (1.29 to 1.82)
   CKD stage 4--5 (n=521)      22.75 (19.81 to 26.12)   5.64 (4.75 to 6.70)           2.60 (2.09 to 3.24)
  *Women, CG (N=8794)*                                                                
  In-hospital mortality                                                               
   Per 10 mL/min decline       1.47 (1.41 to 1.53)      1.29 (1.23 to 1.36)           1.22 (1.14 to 1.30)
   CKD compared with non-CKD   5.52 (4.46 to 6.84)      2.28 (1.78 to 2.92)           1.87 (1.40 to 2.49)
   CKD stage 1 (n=1675)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=2731)        2.25 (1.41 to 3.59)      1.26 (0.78 to 2.04)           1.32 (0.73 to 2.36)
   CKD stage 3 (n=3485)        7.42 (4.85 to 11.39)     2.47 (1.54 to 3.96)           2.09 (1.17 to 3.73)
   CKD stage 4--5 (n=900)      20.38 (13.12 to 31.66)   5.23 (3.15 to 8.70)           3.51 (1.87 to 6.56)
  Long-term mortality                                                                 
   Per 10 mL/min decline       1.43 (1.40 to 1.46)      1.26 (1.23 to 1.30)           1.16 (1.12 to 1.19)
   CKD compared with non-CKD   4.55 (4.11 to 5.04)      2.00 (1.78 to 2.25)           1.71 (1.47 to 1.99)
   CKD stage 1 (n=1675)        1.00 (reference)         1.00 (reference)              1.00 (reference)
   CKD stage 2 (n=2731)        1.93 (1.57 to 2.38)      1.14 (0.92 to 1.41)           1.38 (1.05 to 1.82)
   CKD stage 3 (n=3485)        5.71 (4.72 to 6.92)      2.04 (1.64 to 2.53)           2.17 (1.64 to 2.87)
   CKD stage 4--5 (n=900)      15.41 (12.62 to 18.82)   4.26 (3.37 to 5.39)           3.03 (2.23 to 4.11)

\*Adjusted for age, smoking, diabetes, hypertension, previous MI, previous PCI, previous CABG, chronic heart failure, previous stroke, chronic obstructive pulmonary disease, dementia, peripheral artery disease, previous cancer and therapy on arrival, and, regarding long-term mortality analyses, also therapy at discharge.

CABG, coronary artery bypass grafting; CG, Cockcroft-Gault; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study formula; MI, myocardial infarction; PCI, percutaneous coronary intervention.

![Kaplan-Meier survival curves per chronic kidney disease (CKD) stages, women and men. Comparisons between CKD groups, Wilcoxon (Gehan) Statistics, p\<0.001 for all comparisons except between CKD 4 and 5 in men (p=0.40 and 0.30, Modification of Diet in Renal Disease Study (MDRD) and Cockcroft-Gault (CG), respectively).](bmjopen2015008188f02){#BMJOPEN2015008188F2}

Outcome, women versus men {#s3d}
-------------------------

Women had more than doubled in-hospital and almost doubled long-term mortality than men. After adjustment for age, women still had 22% higher risk of in-hospital and 6% higher risk of long-term mortality. After multivariable adjustments including all confounders except kidney function, women still had 11% higher risk of in-hospital mortality but men had 7% higher risk of long-term mortality. If eGFR according to any of the formulas was also included, there was no longer a gender difference regarding in-hospital mortality, and women had a lower risk of long-term mortality. Adjusting for eGFR according to CG alone was enough to eradicate the higher risk in women, both short-term and long term, and changed the OR and HR more than the multivariable analyses that did not include kidney function ([figure 3](#BMJOPEN2015008188F3){ref-type="fig"}).

![Logistic and Cox proportional hazard regression models of in-hospital and long-term mortality. OR and HR with 95% CIs, women versus men (CG, Cockcroft-Gault; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study).](bmjopen2015008188f03){#BMJOPEN2015008188F3}

Sensitivity analysis {#s3e}
--------------------

We also performed analyses on the limited population where CG was possible to estimate (70%=26 586). The results were very similar (see online supplementary tables S1--S4).

Discussion {#s4}
==========

The key findings in this study were that the prevalence of CKD in women with STEMI was very high and female gender was independently associated with CKD at admission in STEMI. In addition, reduced kidney function per 10 mL/min decline in eGFR regardless of the formula used was a strong and independent risk factor for short-term and long-term mortality in both genders without a significant gender difference in prognostic impact. Reduced GFR appeared to be an important reason why women had doubled mortality compared with men with STEMI.

Earlier studies have shown that in-hospital mortality varies from 1% in patients with normal kidney function (CKD stage 1) to 12--35% in those with severe renal dysfunction (CKD stage 4--5).[@R2] [@R6] CKD, defined as eGFR below 60 mL/min, has also been shown to be more common in patients with MI with prevalence around 30%[@R1] [@R2] [@R6] compared with 6--8% in the general population.[@R18] [@R19] We found a remarkably high prevalence of CKD in women with STEMI. According to the Health Survey of Nord-Trondelag County (HUNT II) study, 5.7% of women and 3.6% of men in the general Nordic population have CKD stage 3--4 according to MDRD.[@R18] The corresponding figures in our cohort were 38% and 19% of women and men, respectively. If we instead used the CG formula, which has been shown to better predict outcome in patients with MI than MDRD,[@R9] as many as half of the women had CKD compared with 22% in men. There was a remarkable impact of age on CKD prevalence, especially when CG was used ([figure 1](#BMJOPEN2015008188F1){ref-type="fig"}).

Thus we thought it important to analyse the association between eGFR and outcome in both genders. Although women with STEMI have a worse outcome than men,[@R10] few studies have investigated the role of renal impairment. Two small single-centre studies, one including mixed patients with coronary artery disease (CAD) undergoing coronary angiography and one including patients with STEMI undergoing primary PCI, found a very high prevalence of CKD in women, based on the MDRD formula (67% vs 70%). Even more remarkable was that both studies found a stronger prognostic impact of CKD in women compared with men,[@R13] [@R20] something that we could not confirm in our study. We found no interaction between gender and eGFR with either of the formulas, neither on short-term nor long-term mortality. After multivariable adjustment, there was approximately 10% and 30% increased risk of short-term and long-term mortality per 10 mL decline in eGFR in both genders with both formulas. A possible explanation for the contradictory findings compared with the previous studies could be the higher prevalence of CKD in women compared with the present study, and differences in comorbidities and multivariate adjustments. In the STEMI study, there were few men with advanced CKD and thus few events in this group, which could explain the discrepant results. As both these previous studies were small, their findings could also be a matter of chance. The magnitude of the present study gave us better power to explore the influence of renal function in relation to gender.

In the present study, women had doubled in-hospital mortality compared with men. After adjusting for baseline differences including 27 covariates, women still had 11% higher risk of in-hospital mortality, consistent with previous findings.[@R10] When eGFR according to any of the two formulas was adjusted for, there was no longer any gender difference in early mortality. In fact, adjusting for eGFR according to CG alone reduced the OR of in-hospital death from 2.12 (95% CI 1.96 to 2.29) to 0.99 (95% CI 0.87 to 1.11). Further adjustment did not alter the results substantially. Regarding long-term mortality, the same pattern was seen.

The higher prevalence of CKD in women could thus explain, to a great extent, the gender difference in mortality. It is likely, by adjusting for renal function alone, that several more adjustments can be made, as many risk factors, such as hypertension and diabetes, and especially age, covary with renal function both in men and women.[@R1] [@R6] The difference in adjustments was more pronounced with the CG formula than with the MDRD formula. Even though the two renal function equations both incorporate age in the equation, they handle the variables differently mathematically. In the present study, we could show that prognosis following an MI, both short-term and long term, is better described by the CG formula in men and women, and this is consistent with previous studies.[@R9] It is, however, unknown which of the two formulas better reflects the true underlying renal function in the STEMI population. The most accurate way to measure kidney function is to measure GFR with an injected exogenous marker such as, for example, iohexol. In clinical practice, this is too cumbersome and, instead, estimating GFR has become routine practice. Neither of the two most common formulas were developed for cardiac patients. The CG formula was developed in the 1970s from a cohort of 249 men treated for a variety of diseases at medical wards[@R7] and the MDRD formula was developed in the 1990s from a cohort of 1628 patients with CKD of both genders.[@R8] They differ somewhat in their estimations in populations with varying gender, age and weight, and are recommended for different purposes: CG for dose adjustments, MDRD for detection of CKD. In spite of MDRD being developed on both genders but CG only in men, it has been shown that the relative error (bias) of CG predictions is associated with age and BMI but not with gender, whereas MDRD has been found to underestimate GFR in women. Equations for prediction of kidney function include a correction factor that lowers the prediction in women to compensate for the gender-dependent difference in creatinine (ie, muscular mass). The difference in muscular mass between men and women was found to be adequately predicted by the CG but overestimated by MDRD according to a study by Cirillo *et al*.[@R21] In the same study, the authors hypothesise that the strong influence on renal function using the CG formula could partly be due to an overestimation of the association of ageing with decline of muscular mass. This could be an additional factor explaining the very high prevalence of CKD in women in our study, as they are clearly older than the men.

The reason for the poor outcome in patients with concomitant STEMI and CKD is multifactorial.[@R22] It is well known that patients with CKD have a higher prevalence of risk factors such as DM and hypertension.[@R23] Owing to the lower renal function in women, a higher proportion of women compared with men are at risk of contrast-induced nephropathy after PCI. Undertreatment with less reperfusion in women than men with CKD in our study (53.7% vs 84.3% in women and men, respectively) and other evidenced-based therapies also contribute to the reduced survival.[@R24] This gender difference in evidence-based STEMI treatment has been shown before, even in the modern era.[@R27] As an increased risk of major bleeding has been found in women treated with fibrinolytics,[@R28] and CKD is also a predictor of bleeding,[@R29] a fear of these dreadful complications may explain some of the observed difference. Other potential explanations could be the longer delay times in women and a higher prevalence of non-obstructive CAD.[@R27] In our study, the chance of having a coronary angiography performed as well as other evidence-based therapies was lower in patients with CKD, something we adjusted for in the multivariate analysis. The lower use of invasive therapies could be explained by scarce evidence-based data, and a lack of proven efficiency in this group of patients. It is also unknown to what extent CKD was identified in patients with STEMI. The lack of recognition of CKD could represent a missed opportunity for dose adjustment of medications. Many patients with CKD and STEMI may have been treated without any dose-reduction in, for example, glycoprotein IIb/IIIa inhibitors, with more bleeding events as a consequence. It is possible that more women were exposed to higher doses, as they are often older and weigh less. In addition, CKD is associated with several metabolic abnormalities, such as oxidative stress, hypoalbuminaemia, hyperhomocysteinaemia, hyperfibrinogenaemia, insulin resistance, lipid abnormalities, inflammation and derangements in the calcium--phosphate homeostasis, all possibly contributing to an excessive cardiovascular risk.[@R30]

Conclusion {#s5}
==========

Impaired renal function is extremely common in women with STEMI---in fact, half of all women with STEMI had at least moderate renal dysfunction. This is far more common than in the general population. The presence of CKD indicated doubled risk of in-hospital mortality in both genders, and reduced eGFR was found to be a strong and independent risk factor for early and late mortality with equal prognostic impact in both genders. Reduced eGFR appeared to be an important reason why women with STEMI had doubled mortality compared with men with STEMI.
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